A5043360954- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Viral-associated cancers and disorders
- Inflammatory Bowel Disease
- Platelet Disorders and Treatments
- Autoimmune and Inflammatory Disorders
- Cytomegalovirus and herpesvirus research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Body Image and Dysmorphia Studies
- Renal Diseases and Glomerulopathies
- Gastrointestinal disorders and treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- Protease and Inhibitor Mechanisms
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Herpesvirus Infections and Treatments
- Microscopic Colitis
- Diabetes and associated disorders
- Virology and Viral Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- T-cell and B-cell Immunology
- Liver Diseases and Immunity
- Lymphoma Diagnosis and Treatment
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2024
Universitat Autònoma de Barcelona
2024
Beckman Research Institute
2019-2024
City of Hope
2019-2024
Vall d'Hebron Hospital Universitari
2017-2024
Instituto de Salud Carlos III
2024
Hospital Universitario Nuestra Señora de Candelaria
2015-2024
Universidad Internacional De La Rioja
2023
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2021-2022
Hospital Universitario HM Madrid
2021
The fluorescence ubiquitination-based cell cycle indicator (FUCCI) is a powerful tool for use in live cells but current FUCCI-based assays have limited throughput terms of image processing and quantification. Here, we developed lentiviral system that rapidly introduced FUCCI transgenes into by using an all-in-one expression cassette, FastFUCCI. approach alleviated the need sequential transduction characterisation, improving labelling efficiency. We coupled to automated imaging workflow...
Objective To describe the baseline characteristics of patients with positivity for antiphospholipid antibodies (aPLs) who were enrolled in an international registry, Antiphospholipid Syndrome (APS) Alliance Clinical Trials and International Networking (APS ACTION) clinical database repository, overall by laboratory subtypes. Methods The APS ACTION registry includes adults persistently had aPLs. We evaluated sociodemographic aPL‐related classification criteria “non‐criteria”) subgroups...
Objective Although systemic lupus erythematosus ( SLE ) is the most common autoimmune disease associated with antiphospholipid antibodies aPL ), limited data exist regarding impact of on clinical phenotype ‐positive patients. The primary objective this study was to compare clinical, laboratory, and treatment characteristics patients those without SLE. Methods A secure web‐based capture system used store patient demographic ‐related laboratory characteristics. Inclusion criteria included...
A gene, phl, encoding a phenylacetyl-CoA ligase was cloned from phage library of Penicillium chrysogenum AS-P-78. The presence five introns in the phl gene confirmed by reverse transcriptase-PCR. encoded an aryl-CoA closely related to Arabidopsis thaliana 4-coumaroyl-CoA ligase. Phl protein contained most amino acids defining (4-coumaroyl-CoA) substrate-specificity code and differed acetyl-CoA other acyl-CoA ligases. not linked penicillin cluster. Amplification autonomous replicating plasmid...
Objective To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob‐ APS ) in a multicentre database antibody ( aPL )‐positive patients, and clinical utility adjusted Global Antiphospholipid Syndrome Score aGAPSS ), validated tool to assess likelihood developing new thrombosis, this group patients. Design Retrospective study. Setting The Alliance for Clinical Trials International Networking Database Repository. Population Women Ob‐ . Methods...
This study aimed to use cluster analysis (CA) identify different clinical phenotypes among antiphospholipid antibodies (aPL)-positive patients.The Alliance for Clinical Trials and International Networking (APS ACTION) Registry includes persistently positive aPL of any isotype based on the Sydney syndrome (APS) classification criteria. We performed CA baseline characteristics collected retrospectively at time registry entry first 500 patients included in registry. A total 30 data points were...
Abstract Background and Aims To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 comparison who maintain Remicade®. Methods Patients under were remission standard dosage at study entry included. The ‘switch cohort’ [SC] comprised made switch CT-P13, ‘non-switch’ cohort [NC] remained Results A total of 476 included: 199 [42%] SC 277 [58%] NC. median follow-up was 18 months 23 NC [p < 0.01]. Twenty-four out relapsed NC; incidence relapse 5% per...
Primary infection with Epstein-Barr virus (EBV) is associated acute infectious mononucleosis, whereas persistent chronic diseases such as autoimmune and various types of cancer. Indeed, approximately 2% all new cancer cases occurring annually worldwide are EBV-associated. Currently, there no licensed EBV prophylactic vaccine. Selection appropriate viral protein subunits critical for development an effective Although the major surface glycoprotein gp350/220 (gp350) has been proposed important...
Epstein-Barr virus (EBV) is an oncogenic human herpesvirus associated with ~350,000 cases of lymphoid and epithelial malignancies every year, etiologically linked to infectious mononucleosis multiple sclerosis. Despite four decades research, no EBV vaccine candidate has yet reached licensure. Most previous attempts focused on a single viral entry glycoprotein, gp350, but recent data from clinical pre-clinical studies, the elucidation mechanisms, support inclusion glycoproteins in design.
Genetically engineered mouse (GEM) models of cancer currently comprise the most accurate way to experimentally recapitulate human disease in laboratory. Given recent advances genomics and genetic screens, however, as well an increasing urgency for translation effective preclinical treatments into clinic, there is a pressing need make these easier more efficient work with. Accordingly, we have developed versatile lentivirus-based approach induce tumours from somatic cells GEMs, add or...
Purpose: To report the effect of adalimumab on serum cytokines in chronic refractory uveitis.Methods: Prospective study effects cytokine levels at different time points a cohort 12 uveitis patients. Results were analyzed according to clinical outcomes and compared with systemic steroid-treated recurrent patients.Results: Before treatment, patients exhibited significantly increased IL-1β, IL-6, TNFα, IL-12 p70, IL-10, IL-22. Adalimumab decreased IL-12p70 early (after 1 month treatment). IL-10...
Kaposi sarcoma-associated herpesvirus (KSHV) is an emerging pathogen and the causative infectious agent of sarcoma two malignancies B cell origin. To date, there no licensed KSHV vaccine. Development effective vaccine against continues to be limited by a poor understanding how virus initiates acute primary infection in vivo diverse human types. The role glycoprotein H (gH) entry mechanisms remains largely unresolved. characterize requirement for gH viral life cycle determination tropism, we...
The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. secondary objectives were (1) characteristics differ between patients with and unstable profiles, (2) predictors of time.A profile defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β2 glycoprotein-I (anti-β2-GPI) IgG/M ≥ 40...